COVID-19 Human IgM PharmaGenie ELISA Kit (NP/S1 RBD) (SBRS1734)

The COVID-19 Human IgM PharmaGenie ELISA Kit from Assay Genie is an indirect immunoassay built to detect human IgM antibodies directed against SARS-CoV-2. The microplate is pre-coated with two recombinant viral antigens: the nucleocapsid protein (NP) and the S1 subunit receptor binding domain (RBD), a dual-target configuration that broadens coverage of the early humoral response.

IgM typically appears in serum within days of symptom onset, making this assay useful for research on acute-phase infection, seroconversion timing, and vaccine-induced antibody kinetics. Investigators studying seroprevalence, post-infectious immunity, or the longevity of the anti-SARS-CoV-2 response use IgM-specific capture to characterize the early window before IgG dominates.

Key practical details: the procedure uses approximately 100 μL of serum per well, with sequential incubation and wash steps performed at room temperature. The conjugate is HRP-based, and the substrate reaction produces a measurable color change read on a standard plate reader. The qualitative result is calculated against an assay-specific cut-off, supporting clear positive and negative discrimination in human samples. The kit is engineered for human-specific IgM detection, with no significant cross-reactivity observed against common cold coronaviruses (HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1) under the recommended conditions.

For research use only. Store reagents refrigerated, protect from light, and avoid repeated freeze-thaw cycles of reconstituted components. Each kit ships with a pre-coated 96-assay plate, wash buffer, calibrators, detection antibody, substrate, and stop solution.